The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

This drug may reduce the risk of addiction to pain medications by decreasing reliance on opioids to reduce pain.

Are you reluctant to invest in stocks right now? That's understandable. Fear, uncertainty, and doubt have become the norm in early 2025 with rising stock market volatility. David Jagielski(Eli Lilly): ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine), an oral NaV1.8 inhibitor, as a treatment for acute pain, representing ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

When disasters occur, organizations such as SCAN Health Plan take a holistic approach, considering the needs of members, providers, brokers, employees and the broader community.

Physiological and pharmacological differences will be described. In addition, focus will be turned on medication management in the acute setting. Unfortunately, many medications have not been ...

20, 2024. It approved Vertex's non-opioid drug Journavx for treating acute pain on Jan. 30, 2025. I fully expect both of these drugs will be huge growth drivers for Vertex. Alyftrek is taken once ...